Management of hematologic toxicity in patients with advanced or metastatic gastric cancer treated with docetaxel , cisplatin and fluorouracil ( DCF ) : Results of monocentric experience

@inproceedings{Salvatore2014ManagementOH,
  title={Management of hematologic toxicity in patients with advanced or metastatic gastric cancer treated with docetaxel , cisplatin and fluorouracil ( DCF ) : Results of monocentric experience},
  author={Turano Salvatore and Biamonte Rosalbino and Conforti Serafino and Mastroianni Candida Maria and Manfredi Caterina and Palazzo Salvatore},
  year={2014}
}
  • Turano Salvatore, Biamonte Rosalbino, +3 authors Palazzo Salvatore
  • Published 2014
Background: Gastric adenocarcinoma is the second most common cause of cancer death worldwide. There is no standard regimen of chemotherapy for metastatic disease, although the regimen of ECF is the most used regimen, with a median survival of 7-9 months. With new regimens of chemotherapy, such as DCF, the median survival has increased, despite a major… CONTINUE READING